Last reviewed · How we verify
low-dose dexamethasone
Low-dose dexamethasone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.
Low-dose dexamethasone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors. Used for Multiple myeloma (in combination with lenalidomide and bortezomib), Cerebral edema, Autoimmune and inflammatory conditions.
At a glance
| Generic name | low-dose dexamethasone |
|---|---|
| Also known as | Dexamethasone sodium phosphate |
| Sponsor | Celgene |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Dexamethasone is a synthetic glucocorticoid that acts as an immunosuppressant and anti-inflammatory agent. At low doses, it modulates immune cell function, reduces cytokine production, and decreases inflammatory responses. It is used in various conditions where immune suppression or inflammation reduction is therapeutically beneficial.
Approved indications
- Multiple myeloma (in combination with lenalidomide and bortezomib)
- Cerebral edema
- Autoimmune and inflammatory conditions
Common side effects
- Infection
- Hyperglycemia
- Insomnia
- Mood changes
- Osteoporosis (with chronic use)
- Hypertension
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (PHASE3)
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (PHASE3)
- Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss (PHASE1, PHASE2)
- Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy (PHASE2)
- Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer (PHASE2, PHASE3)
- LBL-2016 for Children or Adolescents in China (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- low-dose dexamethasone CI brief — competitive landscape report
- low-dose dexamethasone updates RSS · CI watch RSS
- Celgene portfolio CI